ALK and non-small cell lung carcinoma: A unique decentralized clinical trial involved a tumor-agnostic approach using the FDA-approved oral ALK inhibitor alectinib to target ALK fusions (since prior anecdotes suggested responsiveness), with ALK fusions being an ultra-rare genomic alteration found in only ~0.2% of malignancies outside of non-small cell lung cancers (NSCLCs)31,32.